NeuroSense Therapeutics Warrant
NRSNW
4 hedge funds and large institutions have $224K invested in NeuroSense Therapeutics Warrant in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 2 closing their positions.
20% less funds holding
Funds holding: 5 → 4 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
63% less capital invested
Capital invested by funds: $605K → $224K (-$381K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$25.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$388K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$27K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EAM
1
Empery Asset Management
New York
| $96K | – | – | – |
|
2
Hudson Bay Capital Management
Stamford,
Connecticut
| $90K | – | – | – |
|
|
CS
3
Clear Street
New York
| $24K | +$25.4K | +40,138 | New |
|
|
WAM
4
Warberg Asset Management
Winnetka,
Illinois
| $14K | -$27K | -42,610 | -64% |
|
|
AC
5
Armistice Capital
New York
| – | -$388K | -425,000 | Closed |
|
|
6
UBS Group
Zurich,
Switzerland
| – | -$4K | -4,491 | Closed |
|
NRSNW Hedge Fund Activity: Q1 2022 in Review
4 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics Warrant (NRSNW) for Q1 2022, worth a combined $224K — down 63% from $605K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of NRSNW and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest buyer was Clear Street, opening a new position worth an estimated $25.4K. The largest seller was Armistice Capital, exiting entirely with an estimated $388K sold.
- 4 institutional investors held NeuroSense Therapeutics Warrant (NRSNW) as of Q1 2022, down from 5 in Q4 2021.
- Funds reported $224K of NeuroSense Therapeutics Warrant stock for Q1 2022, down 63% quarter-over-quarter.
- 1 fund opened new NeuroSense Therapeutics Warrant positions in Q1 2022 and 2 closed out, a net change of -1 holder.
- The largest NeuroSense Therapeutics Warrant buyer in Q1 2022 was Clear Street, an estimated $25.4K added.
- The largest NeuroSense Therapeutics Warrant seller in Q1 2022 was Armistice Capital, an estimated $388K sold.
Based on aggregated 13F filings for Q1 2022.